The sparing of the parotid glands in the treatment of head and neck cancers is of clinical relevance as high doses to the salivary glands may result in xerostomia.
(and/or low dose target) and the overlapping volume of the parotid gland and the intermediate dose target is less than 25%, the parotid mean dose is likely less than 26 Gy. If the parotid overlaps with the low dose target only then the mean dose to the parotid is likely to be less than 26 Gy. This finding will prove as a very useful guide for the physicians and planners involved in the planning process to know prior whether the parotid glands will be able to be spared with the current set of target volumes or if revisions are necessary. This work will serve as a helpful guide in the planning process of head and neck target cases. 
| IN TR ODUCTION
The treatment of head and neck cancers has evolved in recent years from static IMRT (generally 7-9 fields) to the state of the art arcbased technologies of Volumetric Modulated Arc Therapy (VMAT) and helical delivery i.e. Tomotherapy, which has been necessary as a result of the complexity of the target volumes and their proximity to numerous organs-at-risk (OARs). OARs of concern are: the spinal
------------------------
canal, submandibular glands, brachial plexi, mandible, cochleae, optic apparatus, superior/inferior constrictors, and the parotid glands. The sparing of the parotid glands is the main focus of this paper. This is of clinical importance since high doses to the salivary glands results in a reduction of salivary output and a change in its composition, which in turn may lead to xerostomia, a major cause of decreased quality of life for this set of patients.
1,2 Per Roesink et al, treatment
planners should aim for a mean parotid gland dose less than 39 Gy leading to a complication probability of 50%. 3 However, per studies by Eisbruch et al, in order to retain salivary function of the parotid glands, the mean parotid gland dose must be at or below 26 Gy. 4 A correlation between mean parotid dose and the fractional reduction of stimulated saliva output at 6 months after the completion of radiation therapy was observed in studies of Chao et al 5 In recent studies by Gensheimer et al, the overlap of the parotid gland with a 1 cm expansion of the combined targets (combining the various dose levels of the targets) was found to be the best predictor for the mean dose of the parotid glands (D mean ) for static IMRT cases. 6 Prior studies by Hunt et al concluded that dosimetric sparing of the parotid glands resulting in a Dmean < 26.1 Gy for static IMRT plans is feasible if the parotid-PTV overlap is less than approximately 20%. 7 The focus of this study is to determine which parameter is capable of accurately predicting the mean dose of the parotid glands for plans developed using helical arc available on Accuray's Tomotherapy System (Accuray Inc, Sunnyvale, CA, USA). As discussed by Gensheimer, these findings will allow the clinical staff working on the case to determine if the target volumes require alteration to achieve dosimetric objectives before a considerable amount of time is spent planning the case only to discover that the desired sparing of the parotid glands is unachievable. This could avoid delaying the start date of the patient and utilize limited resources more efficiently.
| ME TH ODS AND MATERIALS

2.A | Selection criteria
The following criteria were applied for inclusion of head and neck patients in this study: intact bilateral parotid glands and 2-4 simultaneously treated targets with prescriptions ranging from 54 Gy to 70 Gy. The dose schemes and the primary disease sites for the patients in this study are characterized in Table 1 and Table 2 analysis was also performed to compare the predictive power of different overlapping volumes. Each parotid dose evaluated is considered "positive" if the mean dose is greater than 26 Gy, and "negative" if the mean dose is equal or less than 26 Gy.
2.C | Parotid dose vs. overlap with PTVs of various dose levels
The plans were further stratified by noting whether the parotid volume overlaps with PTVs at various dose levels-high dose: PTV70 or PTV66, medium dose: PTV63 or PTV60, and low dose: PTV56 or PTV54. Here "PTVx" denotes the PTV that is prescribed to receive x Gy.
Specifically, plans were stratified into three groups: (a) Linear regression was done to examine the correlation between parotid mean dose and either OLV HD , or OLV HD05 . ROC analysis was then performed to compare these two parameters as parotid dose predictors and identify optimal thresholds. ROC curves were then generated against OLV HD and OLV HD05 . The areas under the ROC curves were compared to select the best predictor. After selecting the best predictor, an optimal point on the ROC curve was identified to establish a threshold value.
The statistical analysis in this study was performed using R 
| DISCUSSION
It is interesting to observe that when analyzing combined targets and their expansions, the overlap with PTVs only is the better fit compared to overlapping with PTV expansions. This differs from the findings of Gensheimer et al. 6 However, it is plausible, considering This model intentionally does not differentiate between the contralateral and ipsilateral parotids as the model is purely based on overlap volume. It is reasonable to assume that the ipsilateral parotid will tend to share more of an overlap with the target especially the high dose target which in turn will yield an unfavorable mean dose prediction with this model.
The Tomotherapy parameters that were used in this study-2.5 cm field size, .215 pitch, and 3.5 modulation factor-is the standard of practice at our clinical site. These parameters yield plans with desirable dose distributions while maintain reasonable treatment times. Reasonable treatment times are essential not only for efficiency but also for delivery accuracy. It is feasible that a smaller field size and pitch and/or larger modulation factor can result in better parotid sparing but may also result in substandard delivery accuracy and prolonged treatment time. It is beyond the scope of our paper to prove or disprove this hypothesis.
The separation between the ROC curves are not large mainly due to the similar nature of the quantities-overlap between the targets and the parotid. Specifically, for the combined targets with various expansions, the ROC curves are very similar indicating a similar performance if chosen as the predictor. As for the high dose target only, the ROC curve for the optimal threshold for OLV HD05 is better than any threshold with OLV HD by at least 10% sensitivity and specificity. More significant differences may be observed with a much larger dataset.
The ROC curves for combined PTVs with various expansions (method 1) and PTVs stratified by dose levels (method 2) are not significantly separated within each method. However, these ROC curves cannot be compared directly. The ROC curves in Fig. 3 (method 1) are based on the full data set, while the ROC curves in Therefore, the overall performance of method 2 is better than method 1.
Future work includes collecting more data to strengthen the presented model, and applying similar analysis to other normal tissues, such as the duodenum in pancreatic cases. Additionally, this analysis can be used for treatment modality comparison, such as Tomotherapy vs. VMAT which is now widely used for the conformal treatment of complicated tumors.
| CONCLUSION
We analyzed the relation between parotid mean dose and the overlapping volume between parotid and various PTVs and their expansions, and found out that:
1. When the parotid is overlapping with the low dose target only (with overlapping volumes all less than 16% in our data set), the parotid mean dose is likely under 26 Gy.
F I G . 6. ROC analysis of OLVHD, OLVHD05 as predictors for parotid D mean > 26 Gy.
2. When the parotid is overlapping with the intermediate dose target only, but the overlapping volume is less than 25%, the parotid mean dose is likely less than 26 Gy.
3. When the parotid is overlapping with the high dose PTV plus 5 mm expansion, then an overlapping volume of 8.3% could be used as a threshold to predict parotid D mean > 26 Gy.
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